FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

0 Views· 09/07/23
OncLive® On Air
OncLive® On Air
0 Subscribers
0
In Drama

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

Show more

 0 Comments sort   Sort By


Up next